Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 5/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28971808 | 0.94 | ESR2 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3357599 | 0.82 | ALDH1A1 (0.46) | ALDH1A1GAAKDM4EGRM5HPGD | |
| SCHEMBL11553427 | 0.82 | ALDH1A1 (0.50) | ALDH1A1GAAKDM4EGRM5HPGD | |
| SCHEMBL4110299 | 0.82 | RAB9A (0.67) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL8195567 | 0.79 | MAOB (0.53) | ALDH1A1GRM5MAOBAPPTSHR | |
| SCHEMBL6574222 | 0.79 | MAOB (0.53) | CA12CA1CA2CA9CA14 | |
| SCHEMBL4476065 | 0.78 | CYP2A6 (0.54) | ALDH1A1GAAKDM4EHPGDMAPT | |
| SCHEMBL1810628 | 0.78 | GAA (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5211602 | 0.78 | CA2 (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5981846 | 0.77 | CA12 (0.53) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250075147-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS | OSMO LABS, PBC | 2025-03-06 | — | — | US | claimed |
| US-20250075147-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS | OSMO LABS, PBC | 2025-03-06 | — | — | US | disclosed |
| US-20170044208-A1 | SELECTIVE GLUCOCORTICOID RECEPTOR LIGANDS | THE UNIVERSITY OF MANCHESTER (GB) | 2017-02-16 | — | — | US | disclosed |
| US-20170044208-A1 | SELECTIVE GLUCOCORTICOID RECEPTOR LIGANDS | THE UNIVERSITY OF MANCHESTER (GB) | 2017-02-16 | — | — | US | disclosed |
| US-20170044208-A1 | SELECTIVE GLUCOCORTICOID RECEPTOR LIGANDS | THE UNIVERSITY OF MANCHESTER (GB) | 2017-02-16 | — | — | US | disclosed |
| CN-106232613-A | Selectivity glucocorticoid receptor ligands | 曼彻斯特大学 | 2016-12-14 | — | — | CN | disclosed |
| EP-3068790-A1 | SELECTIVE GLUCOCORTICOID RECEPTOR LIGANDS | The University Of Manchester (GB) | 2016-09-21 | — | — | EP | disclosed |
| WO-2015071657-A9 | SELECTIVE GLUCOCORTICOID RECEPTOR LIGANDS | THE UNIVERSITY OF MANCHESTER (GB) | 2016-09-15 | — | — | WO | disclosed |
| WO-2015071657-A9 | SELECTIVE GLUCOCORTICOID RECEPTOR LIGANDS | THE UNIVERSITY OF MANCHESTER (GB) | 2016-09-15 | — | — | WO | disclosed |
| CN-103261176-B | 1, 4-oxazepane derivatives | TAKEDA PHARMACEUTICAL | 2015-06-03 | — | — | CN | disclosed |
| US-6031109-A | Phenoxy-, phenylthio-, benzoyl-alkyleneaminoalkylene-imidazole derivatives as therapeutic agents | KNOLL AKTIENGESELLSCHAFT (DE) | 2000-02-29 | — | — | US | disclosed |
| EP-0934307-A1 | SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE | RHONE-POULENC RORER LIMITED (GB) | 1999-08-11 | — | — | EP | disclosed |
| US-5780642-A | NON-STEROIDAL ANTIINFLAMMATORY AGENT WHICH BLOCKS RELEASE OF ARACHIDONIC ACID FROM PHOSPHOLIPIDS; SIDE EFFECT REDUCTION | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-07-14 | — | — | US | disclosed |
| WO-1998005327-A1 | SUBSTITUTED AROMATIC COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-02-12 | — | — | WO | disclosed |
| WO-1997048697-A1 | SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE | RHONE-POULENC RORER LIMITED (GB) | 1997-12-24 | — | — | WO | disclosed |
| EP-0705251-A1 | IMIDAZOLE DERIVATIVES AS THERAPEUTIC AGENTS | Knoll AG (DE) | 1996-04-10 | — | — | EP | disclosed |
| EP-0399856-B1 | Pteridin-4 (3H)-ones, processes for their preparation and medicaments containing them | LIPHA (FR) | 1995-08-09 | — | — | EP | disclosed |
| WO-1995000493-A1 | IMIDAZOLE DERIVATIVES AS THERAPEUTIC AGENTS | KNOLL AG (DE) | 1995-01-05 | — | — | WO | disclosed |
| US-5270465-A | 4(3H)-pteridinone compounds | LIPHA, LYONNAISE INDUSTRILLE PHARMACEUTIQUE (FR) | 1993-12-14 | — | — | US | disclosed |
| EP-0399856-A1 | Pteridin-4 (3H)-ones, processes for their preparation and medicaments containing them | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1990-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044208-A1 | SELECTIVE GLUCOCORTICOID RECEPTOR LIGANDS | NR3C1, NR3C2, NR5A1 | CA12 4248/4885CA1 3421/4885CA2 4260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.